Reply to the Editor:  by DeMeester, Steven R.
EN BLOC ESOPHAGECTOMY
REDUCES LOCAL
RECURRENCE AND IMPROVES
SURVIVAL COMPARED WITH
TRANSHIATAL RESECTION
AFTER NEOADJUVANT
THERAPY FOR ESOPHAGEAL
ADENOCARCINOMA
To the Editor:
Dr Rizzetto and colleagues1 con-
cluded from their retrospective review
of 58 patients that en bloc esophagec-
tomy is the surgical treatment of
choice for adenocarcinoma after neo-
adjuvant therapy. We, however, inter-
pret this strong statement with
a degree of reservations. A larger pro-
spective study involving 151 patients
(of which 116 had adenocarcinoma)
has previously demonstrated no signif-
icant difference in recurrence and sur-
vival between en bloc transthoracic
and transhiatal approaches.2 The dis-
crepancy of result could be due to sev-
eral reasons.
The authors emphasized that despite
a higher age and comorbidity profiles
in the transhiatal arm, deaths in this
group of patients were all cancer-re-
lated but one. However, surgical com-
plication, particularly pulmonary
infection, is an independent factor as-
sociated with poor survival.3 Older pa-
tients with more comorbidities are
inevitably more predisposed to pulmo-
nary complications. This factor, to-
gether with other functional and
nutritional variables such as preopera-
tive albumin level, weight loss, pulmo-
nary functions, and performance
status, could have skewed the survival
analysis. We feel that by including in-
dices of tumor aggressiveness such as
differentiation, lymphovascular and
perineural invasion status, and the
aforementioned functional and nutri-
tional parameters, a multivariate Cox
regression analysis is a more accurate
means of determining the real impact
of each surgical approach.
Lymph node yield from transhiatal
resections is significantly lower than
that from transthoracic en bloc resec-
tions. The relatively higher proportion
of complete pathologic response in the
transhiatal group (39% vs 25%) could
have been incorrectly overestimated
secondary to fewer lymph nodes re-
trieved. This is reflected in the higher
proportion of patients with stage III
disease in the en bloc group (37.5%
vs 27.8%). The underestimation of pa-
tients with residual disease in the tran-
shiatal group could have led to the
marked difference of 5-year survival
observed between the 2 groups.
We feel that more attention must be
paid to interpreting this study and that
younger and more medically fit pa-
tients might benefit from more aggres-
sive en bloc resection; transhiatal
approach does not necessarily account
for worse oncologic outcomes among
older patients with more comorbid-
ities. If en bloc resection is preferred
based on its more extensive oncologic
dissection, we would be interested in
the authors’ views on 3-field lympha-
denectomy, given the prevalence of
positive cervical nodes shown to be
as high as 24%.4
K. H. Chang, MRCS
O. J. McAnena, FRCSI
Department of Surgery
Galway University Hospital
National University of Ireland
Galway, Republic of Ireland
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LETTERS TO THE EDITORReply to the Editor:
We appreciate the questions and
comments by Drs Chang and McA-
nena in regards to our study, which
demonstrated significantly improved
survival after neoadjuvant therapy
with an en bloc esophagectomy com-
pared with a transhiatal resection.1 Re-
garding the nonrandomized study by
Morganet al that failed to showadiffer-
ence between a transthoracic and tran-
shiatal resection after neoadjuvant
therapy, there are several points that
bear mentioning.2 First, in contrast to
our study, their population was mixed
adenocarcinoma and squamous cell
cancer. Furthermore, although we re-
ported a significantly greater number
of nodes resected with the en bloc re-
section (median 29.5 versus 19 in the
transhiatal group), Morgan et al inex-
plicably reported a median of 13 re-
sected nodes with each procedure.
Last, although our results with tran-
shiatal resection mirror reports from
other centers, their results were un-
usual. They reported a local recurrence
rate of 6% and 5-year survival of 53%
after neoadjuvant therapy and transhia-
tal resection compared with 17% and
22% in our study and 19% and 20%,
respectively, in the randomized Uni-
versity ofMichigan trial.3 These differ-
ences are difficult to explain but may
represent significant selection bias in
the study byMorgan et al and also indi-
cate that although the incision may beery c Volume 137, Number 1 253
REMEDIASTINOSCOPY:
A STATISTICAL
REINTERPRETATION
To the Editor:
We read with considerable interest
the study by Marra and colleagues1
in the April 2008 issue, ‘‘Remediasti-
noscopy in Restaging of Lung Cancer
After Induction Therapy.’’ We do,
however, have some issues with the
statistical interpretation of their
results.
First, there is the reporting of a P
value of 0.0000 in their Table 2.1 A
P value is the probability of observing
the value or more extreme values
given that the null hypothesis is true
(ie, no true difference). Marra and col-
leagues1 give this as 0, which is not
Letters to the Editorsimilar, all transthoracic esophagecto-
mies are not equal.
Drs Chang and McAnena also refer-
ence a report by Kinugasa et al and
raise the concern that pulmonary com-
plications may have adversely im-
pacted long-term survival in the
transhiatal group in our study.4 It is
important to recognize that all patients
in the study by Kinugasa et al had
squamous cell cancer, and many had
3-field lymph node dissections. Pul-
monary dysfunction is more likely in
patients with squamous cancer and
a significant smoking history, and re-
current laryngeal nerve palsy is more
common after a 3-field dissection
than after our 2-field lymphadenec-
tomy. Nonetheless, pulmonary com-
plications are known to be more
common after transthoracic esopha-
gectomy, so this is unlikely to be the
cause of the worse survival in the tran-
shiatal group. We recognize that pa-
tients who had a transhiatal resection
were older and had more comorbid-
ities, and consequently, we analyzed
disease-specific survival for both
groups and showed that the difference
in favor of the en bloc resection was
even more striking. Because all pa-
tients had advanced disease based on
preoperative clinical staging and
many had residual disease after ther-
apy, we do not believe that a Cox anal-
ysis of relatively minor factors such as
lymphovascular invasion and tumor
differentiation would alter or add to
the very clear findings in favor of an
en bloc resection in our data.
We agree that stage migration likely
explains some of the difference in
survival that we found in the group
of patients with complete pathologic
response in favor of the en bloc resec-
tion group. However, the concern of
stage migration is precisely why our
finding of significantly improved sur-
vival in patients with residual disease
after en bloc resection is so important,
because stage migration is not possible
in these patients: they all had residual
disease, and survival in these patients
is known to be poor. In our opinion,254 The Journal of Thoracic andthere is no valid explanation for the
difference in survival we report other
than the type of resection and, in
particular, the reduced incidence of
local-regional recurrence after the en
bloc technique. It is likely that even
in patients thought to have complete
pathologic response, the en bloc resec-
tion provides a survival advantage by
the removal of micrometastatic disease
that would otherwise be left behind
with a transhiatal resection. The ‘‘un-
derestimation of residual disease’’
only applies to the group with sup-
posed complete pathologic response,
and, importantly, this is the only group
without a significant improvement in
survival with the en bloc procedure.
When residual disease was present,
and therefore not underestimated, the
patients who had en bloc resection
had a significant survival advantage
over those who had transhiatal resec-
tion. If Drs Chang and McAnena are
implying that the disease is underesti-
mated even in this group of patients
who had a transhiatal resection, that
may well be true, but that is also the
point: residual disease needs to be re-
moved to provide patients with a sur-
vival advantage, and the en bloc
esophagectomy is the best procedure
to accomplish this objective.
We recognize that some centers
have reported a high prevalence of
upper mediastinal and cervical nodal
disease even with distal esophageal ad-
enocarcinomas, but this has not been
our experience. Our preference is to
carefully watch these areas with serial
computed tomography and positron
emission tomography scans and to
reoperate when necessary for nodal re-
currence. It has not been our experi-
ence that the failure rate for localized
nodal recurrence in these areas is high
enough to justify the added morbidity
of a 3-field dissection in everyone.
On a last note, we ask that readers
keep an open mind about the possibil-
ity, or perhaps probability, that the
type of resection does impact survival
for patients with esophageal cancer
and consider doing a thorough nodeCardiovascular Surgery c January 2009dissection in the chest and abdomen
for all patients, including those who
have had neoadjuvant therapy. After
all, local control is what we as sur-
geons provide to patients with esopha-
geal cancer, and the evidence is
becoming irrefutable that this is best
accomplished with a transthoracic en
bloc esophagectomy.
Dr. Steven R. DeMeester
Department of Surgery
University of Southern California
Los Angeles, Calif
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